QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-kazia-therapeutics-maintains-2-price-target

HC Wainwright & Co. analyst Sean Lee reiterates Kazia Therapeutics (NASDAQ:KZIA) with a Buy and maintains $2 price target.

 whats-going-on-with-kazia-therapeutics-shares-thursday

Kazia Therapeutics announced results from its Phase II/III trial in regards to the treatment of glioblastoma, a type of brain c...

 kazia-therapeutics-shares-are-jumping-today-successful-study-for-brain-cancer-treatment

Kazia Therapeutics reports a 33% improvement in overall survival for newly diagnosed glioblastoma patients using paxalisib in a...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION